Please select the option that best describes you:
How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?
Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation?
Answer from: Medical Oncologist at Community Practice
It depends on the mutation. EGFR mutants after Osimertinib:- If oligometastatic disease: an option is radiation to the oligometastatic spots and continue osimertinib. It is important to re-biopsy as well due to the possibility of small cell transformation. If transformed to small cell, in gener...
Sign in or Register to read more